![]() Registration OPEN! NCCRED symposium: Innovations in therapeutic practice Friday 20th November 11am - 3pm We wish we could see you all face to face, but this year it will be done virtually to accommodate COVID-19 restrictions. The 2020 symposium will focus on innovations in therapeutic practice for methamphetamine disorder. The symposium brings together leading national researchers, including presentations from recipients of NCCRED’s Round 2 Seed Funding Program. Recipients will share the most up-to-date aspects of their work and research around methamphetamine and emerging drug use. ![]() Guest International Presenter: Dr David Goodman-MezaDavid Goodman-Meza, MD, MAS, is an Assistant Professor in the Division of Infectious Diseases at the David Geffen School of Medicine at University of California, Los Angeles, USA. Dr. Goodman-Meza is a Mexican-American physician-scientist. He is a recipient of an NIDA K08 Career Development Award where he is training in the use of natural language processing and machine learning to evaluate outcomes of people who inject drugs who are admitted due to Staphylococcus aureus bacteremia. He is also the Los Angeles principal investigator on a NIDA Clinical Trials network study evaluating buprenorphine for treatment of methamphetamine use disorder. For More information including the full program visit our website Good Clinical Practice training (ICH-GCP) - expressions of interest GCP training is essential for anyone involved in clinical trials and in clinical research as it provides the fundamentals for the conduct of ethical research. NCCRED provides training and certification to clinicians and academics in the Drug and Alcohol Sector as a key element to its research education agenda. Participants who complete the training receive Transcelerate-accredited certification which is internationally recognised and valid for up to 3 years. ![]() NCCRED is seeking expressions of interest to run a course of GCP training online, over a series of sessions via Zoom. The National Centre for Clinical Research on Emerging Drugs is made up of a consortium of the following four institutions |